GlassScriptPhysician profile
Zandra R Rivera
NPI 1134209802
$10,764.59
in general payments reported to CMS, 2019-2025
36 companies · $2,671 in 2025
The $2,671 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,869 · 2022: $2,732 · 2023: $1,209 · 2024: $1,283 · 2025: $2,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,019 · Education: $140 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,019.37 |
| Education | $139.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,282.50 | 2021 | |
| Incyte Corporation | $1,174.01 | 2021-2025 | Jakafi, Monjuvi, Niktimvo |
| Sanofi-Aventis U.S. LLC | $700.64 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $577.71 | 2022-2024 | Pomalyst |
| Daiichi Sankyo INC. | $543.41 | 2021-2025 | Enhertu, Datroway, Vanflyta |
| Celgene Corporation | $477.45 | 2021-2024 | Reblozyl, Onureg, Pomalyst |
| Janssen Biotech, INC. | $449.42 | 2021-2025 | Carvykti, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $443.98 | 2022-2025 | Datroway |
| Regeneron Healthcare Solutions, INC. | $405.81 | 2022-2025 | Libtayo |
| Genzyme Corporation | $378.85 | 2022-2025 | |
| Gilead Sciences, INC. | $345.97 | 2023-2025 | Trodelvy |
| Pharmacosmos Therapeutics INC. | $337.41 | 2022-2025 | Cosela, Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $330.88 | 2021-2024 | Fruzaqla, Livtencity |
| Sobi, INC | $307.84 | 2024-2025 | |
| Abbvie INC. | $260.22 | 2022-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $247.66 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $213.82 | 2022-2025 | |
| Pfizer INC. | $183.62 | 2024 | |
| Amgen INC. | $182.28 | 2021-2022 | |
| Syndax Pharmaceuticals, INC. | $175.85 | 2025 | |
| Stemline Therapeutics INC. | $155.20 | 2021 | |
| Astellas Pharma US INC | $148.94 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $143.79 | 2025 | |
| Edwards Lifesciences Corporation | $135.04 | 2022 | |
| Shionogi INC | $125.00 | 2021 | |
| Sun Pharmaceutical Industries INC. | $119.94 | 2024 | |
| Kite Pharma, INC. | $119.62 | 2023 | |
| Glaxosmithkline, LLC. | $118.50 | 2025 | Ojjaara |
| Karyopharm Therapeutics INC. | $117.31 | 2023 | Xpovio |
| Vifor Pharma, INC. | $115.05 | 2022 | |
| Seagen INC. | $108.20 | 2023 | Padcev |
| Btg International INC. | $96.96 | 2021 | |
| Puma Biotechnology, INC. | $91.07 | 2021 | |
| Epizyme, INC. | $76.40 | 2022 | |
| Gamida Cell INC. | $48.21 | 2025 | Omisirge |
| Legend Biotech USA INC. | $26.03 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zandra Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.